WALTHAM, Mass., Nov. 7, 2018 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has elected Jim Mullen to its board of directors. Mr. Mullen's appointment brings the total number of Thermo Fisher board members to 12.
Mr. Mullen previously served as chief executive officer of Patheon N.V., a leading global provider of pharmaceutical development and manufacturing services, from February 2011 until the company was acquired by Thermo Fisher in 2017. Prior to that, he was with Biogen Idec, Inc. for 22 years, serving as president and chief executive officer from 2000 to 2010. Mr. Mullen is also currently a director at Insulet Inc. and Editas Medicine Inc.
"We are pleased to welcome Jim to our board," said Jim Manzi, chairman of the board of Thermo Fisher Scientific. "With his extensive experience in the pharmaceutical and biotech industry, his perspective will be highly valuable as we continue to build on our industry-leading capabilities for these customers."
Mr. Mullen holds a Bachelor of Science degree in chemical engineering from Rensselaer Polytechnic Institute and a Master's degree in business from Villanova University.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.